Overview

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Status:
Active, not recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The objective of CLI-06657AA1-04 (formerly PB-102-F60) is to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry patients who have successfully completed studies PB-102-F03, PB-102-F20 or PB-102-F30.
Phase:
Phase 3
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.